In this phase II , randomized , open-label , active-controlled , multicenter clinical trial , patients were randomized @:@ to either @ g ferumoxytol ( @ @-mg injections ) or @ g iron sucrose administered as either a slow injection or infusion ( @ doses for dialysis patients and @ doses for nondialysis patients ) .